Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, posted on X about recent paper by I. Schlam et al., titled “Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges” published on Science Direct.
Authors: I. Schlam, S. Loi, R. Salgado, S.M. Swain.
“Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.
- sTILs represent an accessible and highly reproducible biomarker.
- Higher quantities of sTILs are associated with higher rates of pCR in some patients with HER2-positive breast cancer.
- TILs serve as a positive prognostic indicator of recurrence-free survival in early HER2-positive disease.
- In metastatic disease, higher sTILs are a positive prognostic indicator for longer PFS.
- The widespread adoption of sTILs in clinical practice requires additional research.”